Floatz logo

Tpi 287

Brain Cancer

M.D. Anderson Cancer CenterPhase 2Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Davis
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
Virginia Commonwealth University
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Tpi 287 is also rated in:

glioblastomaDormant
CC
Indicative ·
40 / 100
View asset →
breast cancerDormant
C
Indicative ·
36 / 100
View asset →
Hodgkins lymphomaDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →